Samsung BioLogics Co Ltd
207940
Company Profile
Business description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Contact
125, Cheomdan-daero
Yeonsu-gu
Incheon
KORSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,011
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,723.50 | 17.90 | -0.20% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,530.48 | 292.74 | 1.26% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
| SSE Composite Index | 3,359.90 | 2.21 | -0.07% |